Evaluation of Molecular Biomarkers and Response to Therapy in Prostate Cancer

Update Item Information
Identifier 065_Carroll_EBPF2017
Title Evaluation of Molecular Biomarkers and Response to Therapy in Prostate Cancer
Creator Carroll, Emma; Bailey, Erin; Streeter, Jessica; Gill, David; Hahn, Andrew; Agarwal, Neeraj; Maughan, Benjamin
Subject Evidence-Based Practice; Biomarkers, Tumor; Prostatic Neoplasms; Disease-Free Survival; Prostate-Specific Antigen; Neoadjuvant Therapy; Androgen Antagonists; DNA Repair; Neoadjuvant Therapy; Disease-Free Survival; Genetic Variation; Treatment Outcome; Evaluation Study; Poster
Description Prostate cancer is the most common cancer in men. Prostate cancer has a long natural history, and development of metastatic disease may not be detected for approximately 5 years after initial diagnosis. The backbone of therapy for patients with metastatic disease is androgen deprivation therapy (ADT). For patients whose disease has progressed despite ADT, there are many additional treatment options. However, optimal treatment choice and sequencing are unknown. Genetic variations are being increasingly recognized in prostate cancer. These variations may evolve throughout the natural history of the disease, and may affect disease progression and response to different therapies. Most patients who had mutations in AR, PI3K, and DNA repair genes had a lower time to PSA progression compared to the historical cohort
Relation is Part of Evidence Based Practice Posters - 2017
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date Digital 2017
Date 2017
Type Text
Format application/pdf
File Name a
Language eng
ARK ark:/87278/s613054q
Setname ehsl_ebp
ID 1399434
Reference URL https://collections.lib.utah.edu/ark:/87278/s613054q
Back to Search Results